Benchmark Holdings Plc Logo

Benchmark Holdings Plc

Aquaculture biotech providing nutrition and health solutions for sustainable farming.

BMK | IL

Overview

Corporate Details

ISIN(s):
GB00BGHPT808 (+1 more)
LEI:
2138001UQHM4VZGXUJ19
Country:
United Kingdom
Address:
4 PARK SQUARE, THORNCLIFFE PARK, CHAPELTOWN, S35 2PH SHEFFIELD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Benchmark Holdings plc is a leading aquaculture biotechnology company dedicated to driving sustainability in the industry. The company's mission is to provide aquaculture producers with mission-critical products and solutions that enhance farming efficiency, animal health, and welfare. Benchmark's operations are centered around two key divisions: Advanced Nutrition and Health. Its portfolio includes specialized diets, probiotics, vaccines, medicines, and other health products designed to improve productivity and sustainability for its global customer base. By combining biology and technology, Benchmark supports the growth of a sustainable food supply chain.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-18 08:00
Delisting Announcement
Cancellation of Admissions to Trading
English 11.1 KB
2025-08-15 08:00
Delisting Announcement
Last day of trading
English 6.0 KB
2025-08-15 08:00
Delisting Announcement
Benchmark Holdings plc – Last day of trading
English 1.1 KB
2025-08-08 14:06
Delisting Announcement
Update on the cancellation of trading of shares
English 16.2 KB
2025-08-08 14:00
Delisting Announcement
Update on Euronext Oslo Børs approval of the cancellation of the trading of Ben…
English 4.1 KB
2025-08-08 13:55
Delisting Announcement
Benchmark Holdings plc – Decision on date of delisting
English 749 bytes
2025-08-08 13:55
Delisting Announcement
Benchmark Holdings plc – Vedtak om dato for strykning
Norwegian 766 bytes
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 16.7 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights - Attachment: BMK RNS TVR 31 July.pdf
English 82.3 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 361 bytes
2025-07-25 18:37
Delisting Announcement
Result of Tender Offer - Replacement
English 23.9 KB
2025-07-25 18:30
Declaration of Voting Results & Voting Rights Announcements
Correction: Result of Tender Offer, Total Voting Rights and Directors' Interest…
English 77.2 KB
2025-07-25 18:30
M&A Activity
Correction: Result of Tender Offer, Total Voting Rights and Directors' Interests
English 1.1 KB
2025-07-25 08:00
Share Issue/Capital Change
Result of Tender Offer, Total Voting Rights and Directors' Interests - Attachm…
English 68.6 KB
2025-07-25 08:00
Declaration of Voting Results & Voting Rights Announcements
Result of Tender Offer, Total Voting Rights and Directors' Interests
English 842 bytes

Automate Your Workflow. Get a real-time feed of all Benchmark Holdings Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Benchmark Holdings Plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Benchmark Holdings Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.